LFG
CHRS icon

Larson Financial Group’s Coherus Oncology CHRS Stock Holding History

Larson Financial Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$68 – 3797
2026
Q1 		$68 Buy
+40
New +$71 ﹤0.01% 3536
2025
Q3 		– Sell
-79
Closed -$58 – 3477
2025
Q2 		$58 Buy
+79
New +$68 ﹤0.01% 3222
2025
Q1 		– Sell
-147
Closed -$203 – 3089
2024
Q4 		$203 Hold
147
– – ﹤0.01% 2438
2024
Q3 		$153 Sell
147
-71,343
-100% -$97.8K ﹤0.01% 2445
2024
Q2 		$124K Sell
71,490
-2,471
-3% -$4.97K 0.01% 593
2024
Q1 		$177K Buy
73,961
+73,814
+50,214% +$182K 0.01% 438
2023
Q4 		$490 Hold
147
– – ﹤0.01% 1579
2023
Q3 		$550 Buy
+147
New +$679 ﹤0.01% 1569
2023
Q2 		– Sell
-27,409
Closed -$187K – 1577
2023
Q1 		$187K Buy
+27,409
New +$213K 0.02% 318

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Larson Financial Group's CHRS Position: Q2 2026 in Review

Larson Financial Group sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 40 shares — an estimated $68 sold.

Larson Financial Group first reported a position in CHRS in Q1 2023 and held it in 9 quarters. The position peaked at $187K in Q1 2023. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Larson Financial Group reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Larson Financial Group sold 40 Coherus Oncology shares in Q2 2026, an estimated $68.
  • Larson Financial Group first reported a position in Coherus Oncology in Q1 2023 and held it in 9 quarters.
  • Larson Financial Group's Coherus Oncology position peaked at $187K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.